Xinnate is a young biopharmaceutical company built on scientific research about innate defence and healing mechanisms – evolutionary biological systems with the purpose of keeping us healthy.

Xinnate specializes in the development of proprietary peptide-based drugs for prevention and treatment of inflammatory diseases and infections within the areas skin and wounds, surgical materials and and biomaterials. The company was founded in 2019 and is based on 15 years of world class research from Lund University. The first area to be addressed by Xinnate is advanced wound care, and the first product is a hydrogel, the BioC wound gel, aimed for treatment of burn wounds.